Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Status:
Terminated
Trial end date:
2019-12-15
Target enrollment:
Participant gender:
Summary
This is a multi-center phase II study of brentuximab vedotin in combination with bevacizumab
for the treatment of refractory CD-30+ germ cell tumors (GCT) after disease progression on
imaging and/or tumor marker progression documented by serially rising alpha-fetoprotein (AFP)
or beta human chorionic gonadotropin (bHCG) measured on at least 2 consecutive visits and
determined by treating physician to be clinically significant. Patients unable to receive 2nd
line of platinum-based chemotherapy due to toxicity or refusal would also be eligible.